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Abstract
Ž .A surface plasmon resonance SPR protocol is described for the direct kinetic analysis of small antigenic peptides
Ž . Ž .interacting with immobilized monoclonal antibodies mAb . High peptide concentrations up to 2.5 mM and medium mAb
Ž 2. Žsurface densities about 1.5 ngrmm are needed to ensure measurable binding levels, and fast buffer flow rates 60
.mlrmin are required to minimize diffusion-controlled kinetics. Good reproducibility levels in the kinetic constants are
Ž .obtained under these analysis conditions standard deviations below 10% of the mean values . Application of this protocol to
determine the antigenic ranking of viral peptides shows an excellent agreement between SPR and previous competition
Ž .enzyme-linked immunosorbent assays ELISA on the same peptiderantibody systems. q 2002 Elsevier Science B.V. All
rights reserved.
Keywords: Antigen–antibody interactions; Real-time biospecific interaction analysis kinetics; Surface plasmon resonance analysis of small
analytes
AbbreÕiations: C , analyte concentration; EDC, N-ethyl-N X-A
dimethylaminopropylcarbodiimide; ELISA, enzyme-linked im-
munosorbent assay; Fab, antigen-binding fragment of an antibody;
FMDV, foot-and-mouth disease virus; HEPES, N-2-hydroxyethyl-
piperazine-NX-2-ethanesulfonic acid; IC , 50% inhibition concen-50
Ž y1 y1.tration; k , association rate constant M s ; K , associationa A
Ž y1 .thermodynamic constant M ; k , dissociation rate constantd
Ž y1 . Ž .s ; K , dissociation thermodynamic constant M ; k , appar-D s
Ž y1 .ent rate constant s ; mAb, monoclonal antibody; NHS, N-hy-
droxysuccinimide; PBS, phosphate buffer saline; R, SPR response
Ž . Ž .at time t RU ; R , equilibrium response RU ; RI, bulk refrac-eq
Ž . Ž .tive index RU ; R , maximum response RU ; R , total SPRmax tot
Ž .response RU ; RU, resonance units; SDS, sodium dodecylsulfate;
SPR, surface plasmon resonance; t , run start time.on
) Corresponding author. Tel.rfax: q34-93-402-1260.
Ž .E-mail address: andreu@qo.ub.es D. Andreu .
1. Type of research
ŽThe use of SPR biosensors Fagerstam et al.,¨
1992; Malmqvist and Karlsson, 1997; Homola et al.,
.1999 for interaction analysis has made it possi-
ble to obtain affinity and kinetic data for a large
Žnumber of antigen–antibody Brigham-Burke et al.,
1992; VanCott et al., 1994; Oddie et al., 1997;
.England et al., 1997; Houshmand et al., 1999 ,
Ž .protein–protein Wu et al., 1995 , protein–peptide
Ž . ŽLessard et al., 1996 and protein–DNA Cheskis
.and Freedman, 1996 systems. Other relevant appli-
Žcations are epitope mapping Dubs et al., 1992;
.Saunal and Van Regenmortel, 1995 or selective
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concentration analysis of bioactive molecules in
Ž .complex samples Richalet-Secordel et al., 1997 .´
The majority of the direct single-step SPR analyses
Žreported in the literature Altschuh et al., 1992; Wu
et al., 1995; Lessard et al., 1996; Brigham-Burke et
al., 1992; Lemmon et al., 1994; Tamamura et al.,
.1996; Chao et al., 1996; England et al., 1997 in-
volve analytes weighing above 5 kDa. Since the SPR
response is directly related to changes in mass on the
sensing surface, there is an experimental limitation
for direct SPR detection of small analytes, which led
to a golden rule in SPR: immobilize the smaller
binding partner. A clear example of this rule can be
found, for instance, in antigen–antibody interaction
studies where antigens are immobilized on the sensor
surface and the larger antibodies are used as analytes
Ž .Altschuh et al., 1992; Zeder-Lutz et al., 1997 .
When this rule is not suitable for the purposes in
view, alternative SPR approaches are employed, such
Žas multistep sandwich Cheskis and Freedman, 1996;
Huyer et al., 1995; Shen et al., 1996; Lookene et al.,
. Ž1996 or indirect competitive Lasonder et al., 1994,
1996; Karlsson, 1994; Zeder-Lutz et al., 1995; Nieba
.et al., 1996 analysis. However, in antigen–antibody
interaction studies, the general rule is that a high
Žnumber of potential antigens e.g., peptides with key
.residue substitutions are to be screened against a
small set of specific antibodies. Thus, antibody im-
mobilization has clear practical benefits over peptide
immobilization. Comparison between different pep-
tide antigens is meaningful only if they are analyzed
Žunder exactly the same conditions e.g., all injected
.over the same antibody surface . Moreover, large
Ž .analytes e.g., antibodies are more prone to generate
steric hindrance and mass-transport artifacts that af-
fect true kinetic data.
The protocol that we present here is suited for
Ž .direct single-step surface plasmon resonance SPR
analysis of small ligand–large receptor interactions,
Žwhere small peptides are used as analytes injected
.in the buffer continuous flow and monoclonal anti-
Ž .bodies mAb are immobilized on the SPR sensor
chip surface. The protocol has been optimized
and validated using foot-and-mouth disease virus
Ž .FMDV peptides and anti-FMDV neutralizing mAb
as the binding partners, as described elsewhere
Ž .Gomes et al., 2000a,b, 2001a .
2. Time required
2.1. Full kinetic analysis of a peptide–antibody in-
teraction
For routine analyses on a previously prepared
sensor surface, 2–3 h will suffice. Considering also
ligand immobilization and instrument maintenance
procedures, 4–5 h will be required.
2.2. Immobilization of the antibody on the sensor
chip surface
Ž .1 Preconcentration assays: 60 min
Ž .2 Covalent immobilization: 30 min
Ž .3 Testing regeneration conditions: 30 min
2.3. Binding kinetics assays
Ž . Ž .1 Blank injections two runs : 20 min
Ž . Ž .2 Analyte injections sampleq regeneration : 20
min
( )2.4. Data analysis BIAeÕaluation software : 60 min
2.5. Maintenance
Ž . Ž1 Priming the system once a day or each time a
.sensor chip is changed : 10 min
Ž . Ž2 ADesorbB once a week: washing the system
.in harsh conditions : 30 min
Ž . Ž .3 Sanitizing the system once a month : 40 min
Ž . Ž4 Normalizing the signal once a week or when
.buffer is changed : 40 min
3. Materials
3.1. Special equipment
v The protocol has been optimized on a BIAcore
1000 SPR biosensor
v Personal computer working on a Windows envi-
Ž .ronment Windows ’95, ’98, 2000 or NT
v BIACORE control 3.1 software
v BIAevaluation 3.0 software
v Ž .BIAsimulation software optional
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3.2. Certified materials for SPR assays
Certified materials for running SPR assays on the
BIAcoree biosensors are commercially available
Ž .Biosensor, Uppsala, Sweden :
v ŽCM5 sensor chips, certified grade code BR-
.1000-12, package of three chips —carboxymethyl-
ated dextran matrix, with aG4000 RU binding
capacity for a 40-kDa protein standard and with
user-defined binding specificity.
v ŽHBS-EP running buffer code BR-1001-88, 6=
. Ž200 ml —10 mM HEPES N-2-hydroxyethylpipe-
X .razine-N -2-ethanesulfonic acid with 0.15 M NaCl,
3.4 mM EDTA and 0.005% surfactant P20 at pH 7.4.
v ŽAmine coupling kit code BR-1000-50, for 50
. X Žimmobilizations —750 mg N-ethyl-N - 3-dimethyl-
. Ž .aminopropyl carbodiimide EDC , 115 mg N-hydro-
Ž .xysuccinimide NHS , 10.5 ml ethanolamine hydro-
chloride.
v ŽBIAmaintenance kit code BR-1002-22, for 6
. Ž .months normal usage —solutions of sucrose 65 ml ,
Ž . Ž . Ž .glycerol 30 ml , SDS 90 ml , glycine 90 ml ,
Ž .diazolidinyl urea with surfactant P20 60 ml , sodium
Ž .hypochlorite 10 ml .
v ŽBIAnormalizing solution code BR-1003-22, 90
.ml —for normalization of BIACORE probe signal.
3.3. Solutions for surface regeneration
The regeneration procedures corresponding to the
assays described in the present protocol may, in
principle, be carried out using either 50 mM HCl or
10 mM NaOH. The most common regenerating
agents are:
v Ž .acids 10–100 mM HCl, H PO3 4
v Ž .bases 10–100 mM NaOH
v Ž .salts 1–5 mM NaCl
v Ž .detergents 0.5% SDS
v Ždenaturants 8 M urea, 6 M guanidine hydro-
.chloride
3.4. Monoclonal antibodies
Purified mAbs in PBS can be used as stock
solutions for subsequent dilution in the immobiliza-
tion buffer. Generally, mAb stock solutions corre-
Ž . Ž .spond to ca. 20 mg antibody rml PBS and are
diluted to ca. 5 mgrml in the chosen immobilization
buffer.
3.5. Immobilization buffers
Preconcentration assays are performed in order to
establish which is the best immobilization buffer.
Electrostatic preconcentration is best achieved at low
ionic strength. A 10-mM sodium acetate buffer with
pHs5.5 is generally adequate for mAb amine cou-
pling immobilization on a CM5 sensor chip. The
most common immobilization buffers for sensor chip
CM5 are:
v Ž .10 mM sodium formate pHs3.0–4.5
v Ž .10 mM sodium acetate pHs4.0–5.5
v Ž .5 mM sodium maleate pHs5.5–6.0
3.6. Peptides
Peptide 2.5 mM stock solutions in water or 100
mM acetic acid can be prepared for 1000-fold and
subsequent serial dilutions in the SPR running buffer
Ž .HBS . Thus, peptide solutions injected on the bio-
sensor typically range from 2500 to 20 nM in HBS.
4. Detailed procedure
4.1. Preparing the system
System preparation and routine maintenance will
not be described in detail since they are presented in
the instrumentation manuals. These procedures are
almost entirely automated and computer-controlled
through interactive software in an icon-based win-
dows environment.
Ž .i Dock the new sensor chip, replace the HBS
running buffer bottle by a fresh one and prime the
system.
Ž .ii Normalize the probe signal according to the
manufacturer’s instructions.
4.2. Preconcentration assays
Ž .iii Prepare different mAb solutions to test for the
best immobilizing conditions. Different mAb concen-
Ž .trations e.g., 5, 10 and 50 mgrml and immobiliza-
Žtion buffers e.g., 10 mM formate, pH 4.5; 10 mM
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.acetate, pH 5.0; 10 mM acetate, pH 5.5 should be
considered.
Ž .iv Select one out of the four independent CM5
sensor chip flow cells and set the running buffer
flow rate to 5 mlrmin.
Ž .v Inject sequentially 25 ml of each one of the
Ž . Ždifferent mAb solutions prepared in iii 5-min in-
. Ž .jections , with short 1-min pulses of a 1-M ethanol-
Ž .amine hydrochloride solution pHs8.5 between
each injection.
Ž .vi Examine carefully which combination of mAb
concentrationrimmobilization buffer pH is most sui-
table for efficient ligand electrostatic preconcentra-
tion on the sensor chip surface. This corresponds to
the lowest ligand concentration and to the highest pH
giving maximum response. Immobilization condi-
tions leading to extremely high mAb attachment
Ž .rates steep ascent should be avoided.
4.3. mAb immobilization by coÕalent amine coupling
Once immobilization conditions are chosen, the
mAb can be covalently bound to the sensor chip
surface. The amine coupling procedure involves
chemical activation of the CM5 surface carboxyl
groups and subsequent covalent binding to the mAb
primary amino groups.
Ž .vii Prepare the activating mixture by mixing 35
ml of 0.05 M NHS in water with 35 ml of 0.2 M
ŽEDC in water the NHS and EDC solutions must be
kept separately below 0 8C and should be mixed
.immediately before usage .
Ž .viii Select the flow cell and set the running
buffer flow rate to 5 mlrmin.
Ž . Ž .ix Inject 35 ml 7 min of the activating mixture
Ža response will be observed due to a change in the
.refractive index .
Ž . Žx Immobilize the ligand by injecting 35 ml 7
.min of the mAb solution chosen in the preconcen-
tration assays, inspecting carefully the slope of the
response ascent and the maximum level reached.
Ž .xi Block the nonreacted surface active sites by
Ž .injecting 35 ml 7 min of 1 M ethanolamine hydro-
chloride adjusted to pH 8.5. This will also serve to
break remaining ligand-surface electrostatic bonds.
Ž .xii Measure the amount of immobilized ligand
Ž .by subtracting the initial AemptyB flow cell from
Žthe final baseline level 1000 resonance units—RU
2 .
—correspond to a 1-ngrmm ligand surface density .
When performing kinetic analyses, the ligand density
should be as low as possible, provided signal-to-noise
ratios are adequate. Direct detection of small peptide
Ž .antigens ca. 1.5 kDa binding to immobilized mAbs
Ž .ca. 150 kDa on a Biacore 1000 generally requires
immobilization responses of about 1800 RU.
Ž .xiii Test the regeneration conditions of the sur-
face: this is done by repeated cycles of analyte
Žinjection e.g, 25 ml of a 600-nM solution of the
.antigenic peptide specific for the immobilized mAb
Ž .followed by a short pulse 1–3 min of a regenerat-
Žing solution the most common ones are mentioned
.in Section 3.3 . A suitable regenerating agent pro-
vides full recovery of the baseline level at the end of
Žeach cycle while preserving ligand activity checked
by the constancy of analyte binding level in repeated
.cycles .
4.4. Binding kinetics assays
Ž .xiv Dock the sensor chip containing the immobi-
lized mAb, replace the HBS bottle by a new one,
prime the system and normalize the probe signal
according to the manufacturer’s instructions.
Ž .xv Prepare the peptide solutions to be injected.
Six or seven different analyte concentrations, e.g., a
dilution series ranging from 2500 to 20 nM in HBS,
Ž .will suffice. One blank sample buffer only and a
Ž .negative control analyte e.g., scrambled peptide
should be included in the analyses. The regeneration
solution should also be prepared.
Ž .xvi Set the running buffer flow rate to 60
mlrmin on the flow cell containing the immobilized
Žligand for kinetic analyses, buffer flow rates must
be higher than 30 mlrmin to avoid diffusion-con-
.trolled kinetics .
Ž .xvii Program the injection cycle: use the Akin-
ject mode,B which minimizes sample dispersion and
provides user-defined dissociation times in running
Žbuffer. Needle-cleaning operations Apredip needleB
before analyte injection and Aextra clean-upB after
.regeneration should be also included in each cycle
to avoid carry-over. Each cycle comprises two main
steps:
Ž . Ž .a AkinjectB 90 ml 1.5 min of sample solution
Ž .followed by 4 min 240 s dissociation in
running buffer.
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Ž . Ž .b inject 60 ml 1 min of the regenerating solu-
tion.
Ž .xviii Program the peptide binding assays: each
peptide should be analyzed at least at six different
Žconcentrations each corresponding to one injection
Ž ..cycle as described in xvii . Each measurement
should be run at least in triplicate and injections
should preferably follow a random order. Flush the
system whenever a new peptide is to be screened and
prime the system once a day.
4.5. Data processing and analysis
Data processing is done by means of the BIAE-
valuatione software available from Biosensor. Ex-
Ž .perimental curves i.e., sensorgrams corresponding
Ž .to the same analyte at different concentrations are
simultaneously processed. The software includes
several kinetic models and nonlinear least squares
methods to optimize parameter values. Simple ki-
netic models perfectly described by integrated rate
equations use analytical integration, while more
Žcomplex ones e.g., involving mass transport limita-
tions, ligand or analyte heterogeneity, conforma-
tional changes, analyte multivalency or ligand coop-
.erativity use numerical integration.
Ž .xix Open a new BIAevaluation file and, from
there, access all the experimental curves correspond-
ing to a given peptide–mAb system analyzed under
Židentical conditions except for varying peptide con-
.centration . Also from the same file, open the experi-
mental curves corresponding to the blank run and to
the negative-control peptide injections.
Ž . Ž .xx Adjust the time scale abscissa so that ts0
Ž .injection start is the same for all curves, and the
Ž .baseline level ordinate, before injection start so that
it equals 0 RU in all sensorgrams.
Ž .xxi Delete the useless parts of the sensorgrams
Ž .e.g., the regeneration pulses , after which subtract
Ž .the blank run buffer only curve to all the others
Žthis will eliminate buffer response and instrumental
.drifts or artifacts .
Ž .xxii Subtract from each peptide concentration
curve the one from the scrambled peptide, to elimi-
nate nonspecific binding.
Ž .xxiii Fit the set of binding curves by global
curve fitting to those kinetic models compatible with
your system. Judge which one gives the best fit and
Žthe most reliable parameters a 1:1 Langmuirian
behavior—pseudo-first order reaction—should be
expected for the interaction between each antigen
molecule and each one of the Fabs on the immobi-
.lized mAb .
The fitting models are based on AblindB mathe-
matical tools and the Abest fitB depends on the
ability of the fitting algorithm to converge for the
true minimum and on the number of parameters that
can be varied in the model, i.e., the complexity of
Žthe model O’Shannessy et al., 1993; Morton et al.,
.1995 . Therefore, caution must be taken when judg-
ing the Abest fitB from a purely mathematical point
of view. In general, the best choice is the simplest
model of those giving reasonably good fits.
Ž .xxiv Once the Abest fitB is chosen, a further
detailed evaluation should be performed in order to
Žestablish data consistency Schuck and Minton,
.1996 . Different zones of the experimental curves
should be used for fitting purposes. Local fittings
Ž .each sensorgram separately should be done and
compared with globally fitted data. When applicable,
Žanalytical integration methods separate fitting of
.association and dissociation phases should be tested
and compared with numerical integration methods.
ŽThis means that, for a 1:1 interaction pseudo-first
.order kinetics , data should be fitted as follows:
Ž .a global fitting to the 1:1 interaction model
Ž .numerical integration ;
Ž . Ž .b local fitting each concentration separately to
Žthe 1:1 interaction model numerical integra-
.tion ;
Ž . Žc local fitting, separate k rk analytical inte-a d
gration in each one of the separate association
.and dissociation phases .
If kinetic parameters are consistent throughout all
these fits, the kinetic model chosen is most probably
correct and interaction data are meaningful.
5. Results
In this section, examples of the expected results
will be presented for each one of the main stages of
the analysis protocols.
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Ž .Fig. 1. Example of three successive electrostatic pre-concentration assays. A Injection of a 5 mgrml mAb solution in 10 mM acetate
buffer, pH 5.5, leads to an efficient mAb preconcentration on the carboxylmethyl-dextran matrix of the sensor chip and to a satisfactory final
Ž .response level. B Injection of a 5 mgrml mAb solution in 10 mM formate buffer, pH 4.5, leads to a slow and inefficient electrostatic
Ž .preconcentration of the ligand. C Increasing mAb concentration to 50 mgrml in 10 mM acetate buffer, pH 5.5, leads to a fast
preconcentration and to a too high final response.
Ž .Fig. 2. Example of a covalent immobilization of antibody on a CM5 sensor chip. 1 The carboxyl groups are reacted with a NHSrEDC
Ž . Žmixture and reactive NHS esters are formed. 2 The antibody solution is injected and coupling reaction through the primary amino groups
. Ž .from the antibody lysine residues is allowed to proceed. 3 Remaining reactive NHS ester sites are blocked with ethanolamine
Ž . Ž .hydrochloride pH 8.5 . 4 The final antibody surface is ready.
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5.1. Preconcentration assays
Fig. 1 illustrates the results of three sequential
preconcentration assays. Using ca. 1700 RU as a
reasonable immobilization level for the direct kinetic
assay of small peptide binding to an antibody sur-
Žface, situation A 5 mgrml mAb in 10 mM acetate
.buffer, pH 5.5 is clearly the most satisfactory. In B
Ž .5 mgrml mAb in 10 mM formate buffer, pH 4.5 ,
mAb response increases rather slowly and the final
ŽmAb level is insufficient. In contrast, situation C 50
.mgrml mAb in 10 mM acetate buffer, pH 5.5
corresponds to a fast mAb uptake by the surface
resulting in a too high mAb final density.
5.2. Antibody coÕalent immobilization
A standard ligand covalent immobilization moni-
tored by SPR is depicted in Fig. 2. In a first stage
Ž .1 , the EDCrNHS activating mixture is injected
with the consequent increase in the SPR signal due
to a change in the bulk refractive index. The mAb
Ž .solution is then injected and the binding event 2
can be followed in real time. Once the adequate
binding level is reached, the remaining active car-
boxyl-NHS esters are blocked with ethanolamine
Ž .hydrochloride 3 , causing a significant change in the
bulk refractive index. The biospecific mAb surface is
Ž .then ready to be used 4 .
5.3. Binding assays
The binding assays consist of sequential peptide
injection plus regeneration cycles. Fig. 3A shows the
three main stages observed when monitoring the
Ž .biospecific interaction in real time: 1 Analyte bind-
Ž . Ž .ing to the immobilized ligand association . 2
Bound analyte detaching from the immobilized lig-
Ž . Ž . Ž .Fig. 3. A One injection cycle. B Superposition of several binding curves sensorgrams corresponding to distinct injection cycles
Ž .different concentrations of the same peptide .
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Ž . Ž .and dissociation in running buffer . 3 Ligand sur-
face regeneration.
Each cycle corresponds to a new sample, so that
all blanks, controls, different peptide concentrations
Žand assay repeats are covered. When a full set i.e.,
.all concentrations of a given peptide of injection
cycles is finished, the corresponding sensorgrams
can be transformed in order to eliminate irrelevant
Ž .regions e.g., regeneration pulses and to normalize
the time and response axes. This results in the super-
Ž .position of several sensorgrams Fig. 3B , ready to
be processed by the curve fitting software.
Fig. 4. Illustration of the different stages in the analysis of the interaction between an FMDV peptide and an anti-FMDV neutralizing mAb.
Ž . Ž .A Sensorgrams generated by injection of five distinct concentrations of a nonspecific peptide scrambled sequence on an anti-FMDV
Ž .mAb surface. B Sensorgrams generated by injection of five distinct concentrations of a specific FMDV peptide on the same anti-FMDV
Ž . Ž .mAb surface. C Corrected sensorgrams for the specific FMDV peptide-mAb interactions, obtained by subtraction of curves shown in A
Ž . Ž .from the curves shown in B . D Residual data distribution for the association and dissociation phases, after global curve fitting to the 1:1
Ž . Ž .bimolecular interaction model numerical integration . E Linear correlation between the analyte concentration, C, and the apparent rate
Ž . Ž .constant, k , calculated by local curve fitting to the 1:1 bimolecular interaction model analytical integration . F Correlation between fitteds
equilibrium response, R , and analyte concentration, C.eq
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Table 1
Kinetic and affinity data from the SPR analysis of the peptide–immobilized antibody interaction illustrated in Fig. 4
y1 y1 y1 y1w x Ž . Ž . Ž . Ž .Curve fitting Peptide nM k M s k s K Ma d A
4 y3 7Global – 6.2=10 2.6=10 2.3=10
4 y3 7Local, simultaneous k rk 152 6.0=10 2.4=10 2.5=10a d
4 y3 7305 5.8=10 2.6=10 2.3=10
4 y3 7610 5.9=10 2.6=10 2.3=10
4 y3 71220 6.1=10 2.7=10 2.3=10
4 y3 72440 6.2=10 2.9=10 2.1=10
4 y3 7Local, separate k rk 152 6.7=10 2.4=10 2.8=10a d
4 y3 7305 6.2=10 2.6=10 2.4=10
4 y3 7610 5.5=10 2.6=10 2.1=10
4 y3 71220 5.8=10 2.8=10 2.1=10
4 y3 72440 5.9=10 2.7=10 2.2=10
7w xR vs. peptide plot 2.0=10eq
Three different curve fitting methods were tested in order to evaluate the consistency of the fitted parameters.
5.4. Data processing and eÕaluation
Fig. 4 depicts the most important stages in data
processing and evaluation. In A, sensorgrams corre-
sponding to a nonspecific peptide injected on a mAb
surface are shown. The sensorgrams are square-wave
shaped due to a mere refractive index jump, which is
confirmed by the fact that no peptide is bound to the
mAb at the beginning of the dissociation phase. In B,
sensorgrams correspond to a specific interaction be-
tween an injected peptide and the immobilized mAb.
This same interaction is depicted in C, after being
corrected by subtraction of the sensorgrams corre-
Žsponding to the nonspecific peptide analogue shown
.in A . Sensorgrams in C were globally fitted to a 1:1
interaction model, with calculated curves totally co-
incident with the experimental ones and residuals
Ž .randomly distributed around zero Fig. 4D , corre-
sponding to a chi-squared lower than 1. The kinetic
parameters obtained are shown in Table 1. These
sensorgrams were also fitted locally to the same
Ž .kinetic model Table 1 .
Further local fitting was performed using the sep-
Ž .arate k rk model Table 1 and the locally fitteda d
apparent rate constant, k , was plotted against pep-s
Ž .tide to check the linearity k sk =Cqk ex-s a d
Ž .pected for a 1:1 interaction kinetics Fig. 4E . The
locally fitted response at equilibrium, R , was alsoeq
plotted against peptide concentration so that the
Ž .affinity constant K values withdrawn from thisA
plot and calculated by the k rk ratio could bea d
Ž .compared Table 1 .
6. Discussion
6.1. Trouble-shooting
6.1.1. Immobilization is not satisfactory
The immobilization level depends on several fac-
tors, such as ligand concentration, pH, ionic strength,
Ž .activation time EDCrNHS mixture and injection
Ž .time ligand . Generally, lower ligand binding levels
can be reached by decreasing ligand concentration,
pH, activation and contact times or by increasing
ionic strength. Conversely, higher concentrations and
activation or contact times, as well as lower ionic
strength, contribute to increase ligand immobilization
levels.
6.1.2. Baseline responses increase oÕer repeated
cycles
The regeneration step is not efficient and bound
analyte is not fully washed off after each binding
cycle. Regenerating agents must be tested and a
Ž .cocktail approach Andersson et al., 1999a,b may be
required.
6.1.3. Binding leÕels decrease oÕer repeated cycles
There is loss of ligand activity, either due to
ligand inactivation under the analysis conditions em-
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Ž .ployed inadequate buffers, regeneration agents, etc.
Žor to blockage of ligand binding sites extremely
strong analyte-ligand interactions, ineffective regen-
.eration steps . Different immobilization methodolo-
gies or regeneration conditions may solve the prob-
lem.
6.1.4. Expected binding is not obserÕed
If analyte or ligand degradation prior to usage
in the biosensor experiments can be discarded,
then ligand inactivation during immobilization must
be suspected. Alternative immobilization strategies
Žshould be tested e.g., thiol coupling, binding of
biotinylated ligand to a streptavidin surface, immobi-
lization of mAb to an anti-mouse Fc antibody sur-
.face .
6.1.5. Data do not fit to the expected kinetic model
Ž .Generally, antigen–antibody Fab interactions
display a Langmuirian behavior on the biosensor.
Deviations from pseudo-first order kinetics, one of
the most difficult problems to solve in biosensor
Žanalysis Morton et al., 1995; O’Shannessy and Win-
.zor, 1996; Hall et al., 1996 , can arise from several
factors. The consideration is that, when kinetic stud-
ies are to be carried out, mass transport effects must
be minimized. This can be achieved by decreasing
Žthe ligand immobilization level e.g., to the mini-
mum amount giving a satisfactory signal-to-noise
. Žratio , or by increasing buffer flow rate always
higher than 30 mlrmin and as high as sample con-
.sumption, thus, permits , or by increasing analyte
Žconcentration as long as surface binding capacity is
.not saturated . Mass transport influence can be tested
by analyzing the effect of different buffer flow rates
Žon analyte initial binding rates curve slopes at the
.initial stage of the association step . Another precau-
tion aimed to eliminate mass transport effects in
complex dissociation consists in using a ligand solu-
tion instead of buffer during the dissociation phase.
Other common sources of deviation are ligand or
analyte heterogeneity. The first is mainly due to
random immobilization procedures and can be mini-
mized by lowering binding levels or using oriented
methodologies such as streptavidin–biotin or anti-
Fc–Fc indirect immobilization. Analyte heterogene-
ity can be reduced through additional sample purifi-
cation steps.
The sources of deviation most difficult to deal
with are those intrinsic to the binding partners or
phenomena, such as analyte multivalency, avidity, or
Žcomplex binding mechanisms e.g., involving con-
.formational changes . When these effects are pre-
sent, the only way to take them into account is to use
the more complex fitting models included in the
evaluation software, although it may be difficult to
judge whether a good fit corresponds to the real
Ž .binding mechanism Schuck, 1997 .
6.1.6. Buffer and sample refractiÕe indices mismatch
Whenever sample and running buffers are differ-
Ž .ent, nonspecific bulk refractive index RI jumps
Žtake place square-wave shaped signals superimpose
.to the binding curves . Although such bulk RI re-
sponse may be eliminated by subtraction of a blank
run, useful information from stages immediately af-
ter the injection pulse may be lost. Thus, sample
buffer should resemble the running buffer as close as
possible.
6.1.7. Nonspecific binding
Nonspecific binding may become a problem when
using unpurified samples, such as cell lysates, hy-
bridomas, etc. Anyway, nonspecific binding should
Ž .be checked by one of the following ways. 1 Sample
injection on both the specific cell and a reference
cell. This reference cell must be prepared as simi-
Žlarly as possible to the specific one e.g., same
coupling chemistry to immobilize a similar amount
. Ž .of inactivated ligand . 2 Another approach, perhaps
more appropriate, consists of injection of a non-
Žspecific analyte e.g., peptide with randomized se-
.quence .
BIAcore 2000 and 3000 instruments allow to
monitor interactions on the four different sensor chip
cells with a single sample injection, thus, providing
simultaneous analysis of analyte binding to three
different receptors plus a reference cell at minimal
sample costs.
6.2. AlternatiÕe procedures
The direct single-step approach presented here is
the simplest way to study biospecific interactions
and is advisable for kinetic studies. However, some-
times the systems under study cannot be suitably
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characterized by this method and alternative ap-
proaches may be required. Standard alternative SPR
methodologies include the following:
6.2.1. Direct multistep approach
This consists of immobilization of a ligand fol-
lowed by binding of a specific analyte followed by
Žinjection of a second binding partner that binds the
.first analyte is injected. Each binding stage is moni-
tored in real-time and this approach is often em-
Ž .ployed for binding site analysis Dubs et al., 1992
Žand analyte response enhancement Van Regenmor-
.tel et al., 1994 .
6.2.2. Indirect surface-competition assay
This is used in kinetic studies of low molecular
weight analytes and consists of injecting a specific
high molecular weight analyte followed by competi-
tion experiments using the small target analyte as
Ž .competitor Karlsson, 1994 . This requires a macro-
molecule possessing the same binding specificity of
Žthe small target analytes e.g., a viral protein compet-
.ing with a small peptide antigen .
6.2.3. Solution affinity experiments
These are widely employed for small analyte
detection, with the disadvantage that they do not
provide kinetic information. This approach resembles
a competition ELISA experiment in the sense that a
Ž .suitable analyte e.g., native peptide antigen is im-
mobilized on the sensor surface and preincubated
Žmixtures of analyte–receptor e.g., other peptide
.antigensqspecific antibody are injected. Incubating
variable analyte concentrations with a constant re-
ceptor concentration allows to build inhibition curves
Ži.e., free receptor concentration vs. analyte concen-
.tration , from which binding constants can be with-
Ž .drawn Nieba et al., 1996; Gomes et al., 2001b,c,d .
7. Essential references
7.1. Original papers
v ˚Fagerstam, L.G., Frostell-Karlsson, A., Karls-¨
Ž .son, R., Persson, B. and Ronnberg, I. 1992¨
v Ž .Hall, D.R., Cann, J.R. and Winzor, D.J. 1996
v Ž .Karlsson, R. 1994
v Ž .Lofas, S. and Johnsson, B. 1990¨
v Morton, T.A., Myszka, D. and Chaiken, I.
Ž .1995
v Ž .O’Shannessy, D.J. and Winzor, D.J. 1996
v O’Shannessy, D.J., Brigham-Burke, M. and
Ž .Peck, K. 1992
v O’Shannessy, D.J., Brigham-Burke, M., Sone-
Ž .son, K.K., Hensley, P. and Brooks, I. 1993
7.2. ReÕiew papers
v Ž .Garland, P.B. 1996
v Ž .Schuck, P. 1997
v Ž .Homola, J., Yee, S.S. and Gauglitz, G. 1999
7.3. Other sources
v ABiacore instrument handbook,B Biosensor
Ž .1994
v ABIAevaluation software handbook: version
Ž .3.0,B Biosensor 1997
v Ž .ABIAplications handbook,B Biosensor 1994
v http:rrwww.biacore.com
8. Quick procedure
Ž .i Prepare peptide stock solutions, ca. 2.5 mM in
0.1 M acetic acid, and quantitate by amino acid
analysis.
Ž .ii Prepare mAb stock solutions, ca. 15 mgrml
in PBS, and quantitate by measuring optical density
w Žat 280 nm considering 1 OD f0.75 mg pro-280
. xtein rml .
Ž .iii Prepare mAb solutions for preconcentration
assays: start with four to six different solutions, at
different pH and mAb concentrations. For instance,
v 5, 10 and 50 mgrml in 10 mM sodium maleate
buffer, pH 4.5;
v 5, 10 and 50 mgrml in 10 mM sodium acetate
buffer, pH 5.0;
v 5, 10 and 50 mgrml in 10 mM sodium acetate
buffer, pH 5.5.
Ž .iv Prepare a 1-M ethanolamine hydrochloride
Žsolution, adjusting the pH to 8.5 also available from
.Biosensor .
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Ž .v Set the biosensor instrument ready, according
to the manufacturer’s instructions manual:
v Žreplace the HBS running buffer available from
.Biosensor bottle for a new one;
v Ždock a new sensor chip BIAcertified CM5
.sensor chip and prime the system;
v normalize the instrument signal, using the
BIAnormalizing solution.
Ž .vi Select one out the four flow cells on the
sensor chip and set the buffer flow rate to 5 mlrmin.
Ž .vii Program an alternate series of 25-ml injec-
tions, corresponding to the different mAb solutions
Ž .prepared in iii , and 5-ml injections of the 1 M
Ž .ethanolamine hydrochloride prepared in iv .
Ž .viii Decide whether it is necessary to improve
preconcentration levels by adjusting mAb solution
Ž .parameters concentration, pH, ionic strength . If
Ž . Ž .improvement is required, repeat steps iii – vii . If
not, choose the mAb solution giving the best results
Ž . Ž .and follow steps ix and xx below, for covalent
immobilization.
Ž .ix Prepare 0.2 M EDC and 0.05 M NHS solu-
Žtions also available from Biosensor; these solutions,
once prepared, should be divided into 100-ml aliquots
.and stored below 0 8C .
Ž .x Mix 50 ml of the EDC solution with an equal
volume of the NHS solution, and immediately inject
35 ml of this mixture at 5 mlrmin, to activate the
sensor surface. Solutions can be mixed using the
automatic sampling unit of the instrument.
Ž .xi Inject 35 ml of the mAb solution chosen in
Ž .viii . Binding levels can be controlled at this stage
by either interrupting the injection or appending
extra injections of the mAb solution.
Ž .xii Block the remaining active sites on the sur-
face with a 30-ml injection of 1 M ethanolamine
hydrochloride, pH 8.5.
Ž .xiii Prepare solutions for testing regeneration
conditions, starting with the most commonly used for
mAb–peptide binding assays:
v 10 mM HCl;
v 10 mM NaOH.
Ž .xiv Select a peptide expected to bind signifi-
Žcantly to the mAb e.g., the native antigenic se-
.quence and dilute the stock solution to 600 nM in
HBS.
Ž .xv Test the regenerating agents by alternating
injections of 15 ml of peptide and 10 ml of regenerat-
ing solutions. If common regenerating agents are not
adequate, try other possibilities until an agent capa-
ble of restoring the baseline level while keeping
mAb binding activity is found. Then, proceed to the
binding kinetics analyses as described below.
Ž .xvi Prepare a peptide dilution series: 1000-fold
and further serial dilutions of stock solution in HBS,
covering six to eight different peptide concentrations
Ž .e.g., 2500–20 nM . Include the nonspecific peptide
Ž .dilution series and a blank sample HBS only .
Ž .xvii Replace the HBS bottle by a new one,
Ž .prime the system and normalize the signal as in v .
Ž .xviii Set the buffer flow rate to 60 mlrmin.
Ž . Žxix Program the injection cycle relevant opera-
.tional commands shown in italics :
v predip needle in HBS;
v kinject 90 ml of peptide solution plus 240 s
dissociation in running buffer;
v inject 60 ml of the regenerating solution;
v extracleanup needle.
Each injection cycle corresponds to a single ana-
lyte sample. Programmed cycles must cover all pep-
tide concentrations plus nonspecific peptide samples
and blank runs. Flush the system whenever peptide
is changed.
Ž . Ž .xx Prepare raw data obtained in xix for pro-
cessing with the BIAevaluation software: group in
Ž .the same file all binding curves sensorgrams corre-
Žsponding to the same peptide different concentra-
.tions , to the nonspecific peptide and to the blank
runs.
Ž .xxi Following manufacturer’s instructions, nor-
malize all sensorgrams by setting all baseline levels
Ž .to 0 RU response units and all injection starts to
0 s.
Ž .xxii Delete irrelevant parts of the sensorgrams,
such as the regeneration pulses, spikes and alike.
Ž .xxiii Transform the sensorgrams by subtracting
the blank run response.
Ž .xxiv Further correction of the experimental data
is done by subtraction of the nonspecific peptide
Ž .response for a given concentration from the spe-
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Žcific peptide binding curve for the same concentra-
.tion .
Ž .xxv Select the corrected peptide binding curves
and fit them globally to the simplest kinetic model
Ž .1:1 bimolecular interaction , choosing binding curve
regions as wide as possible so that injection pulses
and bulk RI jumps are avoided.
Ž . Žxxvi Fit sensorgrams locally each binding curve
.separately to test for kinetic data consistency.
Ž .xxvii Repeat sensorgram local fitting, now con-
sidering association and dissociation steps separately,
as a further test for data consistency. Check for
Ž .linearity of k s f Conc .s
Ž .xviii Judge on fitting model suitableness and
kinetic data reliability. If results are satisfactory,
proceed to the next peptide. If not, other kinetic
models can be tested or, most probably, the experi-
Žmental setup must be changed starting with mAb
immobilization levels and peptide concentration
.range .
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